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initiation and 65% thereafter for AF and 53% and 59% respectively for VTE. There
was a positive relationship between number of visits during initiation and the
number of subsequent visits (correlation coefficient (r)0.29) and a negative rela-
tionship between number of visits and TTR during both initiation (r-0.3) and
maintenance (r-0.35). CONCLUSIONS: Increasing number of anticoagulation vis-
its was associated with reduced time in range suggesting that despite increased
monitoring some patients fail to stay in range. In addition, patients who require
frequent visits during the initiation phase continue to do so during maintenance,
suggesting that this may be a useful predictor for patients who are likely to be
poorly controlled despite high resource use in the longer term and may hence be
candidates for alternative means of anticoagulation.
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OBJECTIVES: While WHO guidance considers a “misuse” to base national pricing
and reimbursement regulations on ATC/DDD system, in Poland, drugs are reim-
bursed based on costs associated to their corresponding Defined Daily Doses (DDD).
We analysed the group of ACE inhibitors to check whether the observed Prescribed
Daily Doses (PDD) in the Polish setting correspond to DDDs. ACE inhibitors consti-
tute an important therapeutic group in Poland (45 million packs yearly). According
to a recent National Health Fund report, ramipril ranked fifth in terms of total
reimbursement expenditure in 2010 (205 million PLN; 2.4% of the total budget).
METHODS: We used IMS Medical Index report to derive average PDDs for ACE
inhibitors available in Poland. Both monotherapies and fixed-dose combinations
were analysed, irrespective of their prescribed indication. Average Daily Doses
reported for specific preparations were weighted using the actual sales, so that the
results can be interpreted as average PDDs, adjusted to drug use structure. Analysis
is based on year 2010 data. RESULTS: For 10 molecules (benazepril, captopril,
cilazapril, fosinopril, imidapril, lisinopril, moexipril, perindopril, quinapril, tran-
dolapril) the PDDs did not differ more than  0.5 times vs the respective DDDs. On
the contrary, PDD for enalapril and ramipril was significantly higher than DDD (1.8
and 2.9 times the DDD, respectively). This finding is consistent with the prescrip-
tion patterns reported in the German setting – 1.9 and 3.5 times the DDD, respec-
tively (Grimmsmann, Himmel 2010). CONCLUSIONS: New reimbursement law due
to come into force in 2012 may apply a PDD instead of DDD as reference for reim-
bursement, in case DDD is lower than the most frequent dosage. In view of the
above findings, ACE inhibitors should be revised in this aspect. The current practice
of basing limits on DDDs may lead to suboptimal allocation of public funds and
have ultimately negative impact on patients’ access to therapy.
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OBJECTIVES: Evaluation of cardiovascular (CVS) medication prescription in 2010 as
compared to 2005, in relation to age, in the field of primary health care, of Nis region
METHODS: A retrospective study on cardiovascular drugs utilization according to
ATC classification, was conducted on the basis of data received from Central City
Pharmacy Nis, and results were presented in DDD/1000 inhabitants/day RESULTS:
Data analysis confirmed a total increase of CVS medication prescription of 58%
during the research period (251,76:399 DDD/1000inh/d). Thereby, a significantly
higher percentage of prescription was notified among population older than 60 as
compared to younger population (67%: 40%). Except for diuretics, there was an
increasing tendency in all groups of CVS medication prescription in both age
ranges. The highest percentage of prescription was marked in the group of Calcium
antagonist drugs: 95% in patients older than 60 and 84% in younger population.
Beta blockers were prescribed to elderly CVS patients for 29% more than to younger
ones in 2010. The CVS medications prescribed most in the research period were
drugs affecting the renin-angiotensin-aldosterone system (101,5:226,7DDD/
1000inh/d), whereby the increase of usage prevailed among elderly patients
(67%:41%). CONCLUSIONS: The obtained results show a significan increase of CVS
medication prescription, predominantly among elderly patients. The highest per-
centage of prescription was manifested in the group of calcium antagonist drugs as
compared to other medications, in patients of all age groups, whereas no signifi-
cant change in diuretics usage was reflected during the research period.
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OBJECTIVES: AF is the most frequent, clinically significant form of arrhythmia
leading to stroke in a substantial proportion of patients. This paper investigates a
possible OAC underuse based on a large German health insurance data set.
METHODS: Based on data from 2 German statutory medical aid funds (2007-2008),
a patient was considered to be in need of OAC if a CHADS2-Score2 without any
OAC contraindication (CI) had been recorded. We used two CI scenarios; 1) a more
extensive CI list based on the German Summary of product characteristics, and 2)
a more limited list based on latest publications. In our day-specific analysis cover-
ing 2008, we classified each observed day into one of the following 3 categories:
OAC use: day covered by OAC prescription (daily required dose defined by daily
defined dose (DDD) or within a 180-days grace-period after consumption of last
prescription); and Uncertain OAC use: OAC prescription in 2008, but the day was
outside the grace-period, or it was covered by other anticoagulants/antiplatelets
(DDD90 days’ grace-period). OAC underuse: no OAC prescription in 2008, or other
anticoagulants/antiplatelets did not cover the day (DDD-based90 days
grace-period). RESULTS: Data of 183,448 AF patients were included, mean age 73.2
years (SD: 10.97 years), 55.6% male. Their average CHADS2 was 2.8 (SD 1.58). Con-
sidering CI, OAC was recommendable for 54251 (29.6%; scenario 1)/83653 (45.6%;
scenario 2) of all patients. Between 28.1% and 31.8% of all days were OAC use days
whereas 43.0%-48.7% were OAC underuse days. Relative underuse rates did not
differ between the two CI scenarios. Older female patients with a high number of
co-morbidities had a greater OAC underuse probability. CONCLUSIONS: Our anal-
ysis shows that the OAC underuse problem in AF patients in the German health
care system is possibly more widespread than previous observational studies have
shown.
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OBJECTIVES: Assessment and comparison of baseline clinical characteristics, cur-
rent trend of utilization of key evidence-based-medications (EBM) and interven-
tional strategies for ACS patients presented with and without diabetes.METHODS:
This observational cohort study was conducted at The Heart Care Clinic, Ahmed-
abad among patients presented with ACS. In this cross-sectional study, data base
from the clinic was accessed to collect the data. This includes demographic infor-
mation, vital signs, personal particulars and details of other risk factors for ACS
such as diabetes, smoking and family history of coronary artery disease. Also in-
formation pertaining intervention procedure (medical management or percutane-
ous transluminal coronary angioplasty [PTCA] or coronary artery bypass grafting
[CABG]) and medications prescribed at discharge were collected. RESULTS: Among
370 ACS patients, about 30% patients were diabetic. Typically, percentage of hyper-
tensive patients was significantly higher among diabetics compared to non-diabet-
ics (59.29% vs. 38.91%, p0.0004). The difference in proportion of patients on med-
ical management among diabetic and non-diabetic patient population was found
to be highly significant (47.79% vs. 39.30%, p0.0002). Key medications (ACEIs/
ARBs, BBs, statins, and aspirin) were prescribed in 98.2, 85.0%, 87.6%, and 95.6%
diabetic (113); while 97.3%, 82.1%, 93.8%, and 96.5% non-diabetic (257) patients,
respectively on discharge. CONCLUSIONS:Diabetes is highly prevalent among ACS
patient population and the worse prognosis in ACS patients from India may be
attributed to clustering of several cardiovascular risk factors at presentation. The
diabetics are being managed more frequently with cardiovascular medications
rather than revascularization therapy (PTCA or CABG) compared to non-diabetics.
Utilization of evidence-based-medication for both diabetic and non-diabetic ACS is
consistent with the guidelines and recommendations and is not differing among
the diabetic and non-diabetic population; except for the lipid lowering therapy.
This observational study might serve as a maneuver to the current practice and
highlights awareness on the adherence to the recommendations from the guide-
lines.
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OBJECTIVES: To assess the prevalence and pattern of concomitant medication
(CM) use in US adults on statin therapy. METHODS: A retrospective analysis was
conducted using a large, US employer-based claims database. The study cohort
included adults 18 years old with 1 statin prescription between January 1, 2009
and December 31, 2009 with at least 6 months pre- and 3 months post-index (90-
day study period) continuous enrollment. CM use was defined as a drug, excluding
statins, recorded as prescribed to a patient. Data on the prevalence and pattern of
use of CMs, including CMs that potentially interact with statins, were analyzed.
Chi-square analyses were performed to examine relations between prevalence of
CM use (5 CM use vs. 5 CM use) and demographic variables (age groups and
gender). RESULTS: The study included 403,182 statin users, mean age 58 (SD 12)
years, 75% 65 years, and 52% male. Patients were prescribed an average of ap-
proximately 6 CMs during the study period. A total of 334,033 (83%) and 231,508
(57%) patients were prescribed 3 and 5 CMs. The proportion of patients pre-
scribed 5 CMs was significantly higher in females (63% vs. 52%, P0.0001) and
patients 65 years old (72% vs. 52%, P0.0001) compared to males and those 65
years old. Commonly prescribed CMs that potentially interact with statins included
A388 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
